Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is making significant strides in the development of a new class of DNA Damage Response (DDR) therapies, specifically targeting cancers that are difficult to treat. The company announced a key manufacturing milestone: the successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010. This achievement marks a critical step in moving the therapy toward clinical trials and potential commercialization.
Cancers frequently exhibit defective repair of damaged DNA, leading to mutations that drive unchecked growth, immune evasion, and metastasis. Conventional DNA-damaging therapies, such as radiation and certain chemotherapies, can overwhelm a cancer's limited repair capacity, but some tumors retain sufficient repair mechanisms to resist these treatments at tolerable doses. Onco-Innovations is addressing this challenge by developing Polynucleotide Kinase Phosphatase (PNKP) inhibitors, which disrupt cancer cells' ability to repair DNA damage, thereby enhancing the effectiveness of existing therapies.
The company recently signed a Letter of Intent with Nanosoft Polymers to support polymer development, drug delivery optimization, and formulation work for the ONC010 program. This collaboration is expected to enhance the delivery and efficacy of the PNKP inhibitor, potentially improving patient outcomes. The partnership underscores Onco-Innovations' commitment to advancing its pipeline through strategic alliances.
The PNKP inhibitor approach is part of a rapidly evolving area of oncology focused on exploiting DNA repair vulnerabilities in cancer cells. By targeting PNKP, Onco-Innovations aims to create a novel therapeutic option for patients with hard-to-treat cancers that have limited treatment options. The company's progress in manufacturing and formulation development positions it to advance toward preclinical and clinical studies.
Investors can find the latest news and updates relating to ONNVF in the company’s newsroom at ibn.fm/ONNVF. As the company continues to develop its pipeline, the oncology community will be watching for further advancements in this promising area of cancer therapy.
